Lyell Immunopharma, Inc.
LYEL · NASDAQ
Market closed$13.32$-0.570000 (-4.10%)After hours $13.60 · +2.10%
Key statistics
Previous close$13.89
Open$13.81
Day high$13.90
Day low$13.06
52-week high$45.00
52-week low$9.28
Market cap326.40M
Volume168.67K
Average volume150.33K
P/E ratio-0.97
Forward P/E—
EPS-13.80
Dividend yield0.00%
Market context
Why it moved
LYEL shares continued to decline amid broader selling pressure, with the stock down over 11% in the past week, as insider selling by a major 10% owner, Innovative Cellular Therapeutics Holdings, added to negative sentiment despite analysts maintaining bullish price targets.
What is happening
Recent company-specific developments and publisher coverage.
TradingView · July 10, 2026Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% UpsideAd Hoc News · July 3, 2026Lyell Immunopharma updates pipeline strategy as cell therapy field evolvesStock Titan · June 12, 2026Over 100 lymphoma patients get CAR-T with no Grade 3+ CRSStock Titan · June 4, 2026Lyell CAR T study reports low-grade side effects in lymphomaInvesting.com · June 3, 2026H.C. Wainwright reiterates Lyell Immunopharma stock rating at buyGlobeNewswire · February 12, 2026Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaQuiver Quantitative · December 7, 2025Lyell Immunopharma Reports Promising Efficacy Data for Rondecabtagene Autoleucel in Large B-Cell Lymphoma TrialsGlobeNewswire · November 10, 2025Lyell Immunopharma Acquires Exclusive Global Rights to a Mt Newswire · July 13, 2026Lyell Immunopharma Files for Secondary Offering of Common Shares Benzinga · June 15, 2026Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target Benzinga · June 15, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 12, 2026Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97% Benzinga · June 8, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 8, 2026Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update Mt Newswire · June 8, 2026Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study Benzinga · June 8, 2026Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer